A Federal Report Just Told States to Prepare for Psychedelic Approval. Ketamine Clinics Are the Template
The short answer: A new SAMHSA report tells states to start building the budget, licensing, and oversight machinery for psychedelic therapy. It says to do that before the FDA approves anything. Ketamine is not named once. For clinic operators, that absence matters more than an inclusion would.
Liability coverage and certification are two parts of a credentialing conversation clinics can settle before the state starts one. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| What happened | Why it matters to your clinic |
|---|---|
| SAMHSA published Current Research, Regulatory, and Policy Considerations: Psychedelics Medicine on August 26, 2026 | The first federal document telling states to prepare operationally, not just watch the science |
| Covers psilocybin, MDMA, LSD, and a 5-MeO-DMT formulation | Ketamine is excluded because it is already Schedule III and already approved |
| Warns states may cover the drug but not the therapy around it | The exact reimbursement gap ketamine clinics have worked inside for years |
| Asks states to write credentialing and complaint rules now | Regulators drafting those rules will look at the clinics already operating |
What SAMHSA Actually Said
The Substance Abuse and Mental Health Services Administration released the report on August 26, 2026. It says psychedelic-assisted therapy is moving toward clinical practice “faster than most observers anticipated even 5 years ago.” The four substances it covers all hold FDA breakthrough therapy designation.
The instruction to states is to stop waiting. SAMHSA asks officials to “consider planning now for the fiscal, legal, and operational implications of potential FDA-approved psychedelic therapies.” It also wants states developing “credentialing standards, safety protocols, informed consent processes, and complaint mechanisms” before these drugs arrive.
This is not a promotional document. The report says the evidence base “remains uneven and important methodological limitations persist.” It follows the April 2026 executive order directing agencies to accelerate psychedelic research.
The Medicaid Trap Ketamine Clinics Already Live In
One passage should stop every clinic owner mid-page. SAMHSA warns that “State Medicaid agencies could theoretically cover the drug but not the associated services.” That creates a dilemma, because “the evidence for benefit appears inseparable from the therapeutic framework.”
Ketamine clinics have operated inside that gap for a decade. Payers reimburse the infusion code readily enough. What gets denied is the monitoring time, the integration sessions, and the staffing that make treatment work. SAMHSA is describing as a future psilocybin risk the structure that already governs ketamine economics.
Why the Ketamine Omission Cuts Both Ways
Ketamine appears nowhere in the report, and that is correct. It is Schedule III, approved as an anesthetic, and prescribed off-label for depression. Spravato gave it an approved derivative years ago. Ketamine does not need the pathway SAMHSA describes.
But states will not draft credentialing standards in a vacuum. They will study the psychedelic-adjacent care already running inside their borders. In most states, that means ketamine clinics. Texas showed how fast a medical board can rewrite ketamine rules once it decides oversight is thin. Regulators writing psilocybin rules will use the ketamine clinic down the road as their working reference.
The Finding Almost Nobody Is Quoting
SAMHSA also flags a gap in the research. Psychedelic trials have largely excluded the populations state mental health systems actually serve. That means people with serious mental illness, low incomes, and complex trauma histories.
Ketamine carries a version of the same problem. Cash-pay pricing selects for patients who can absorb several thousand dollars out of pocket. A Medicaid agency will ask about a very different group. Oregon’s psilocybin program already produced safety data that looks worse at three months than at three days. Regulators will want that evidence before writing any coverage rule.
What Clinic Owners Should Do Before Their State Moves
The window to shape these frameworks is open while they are drafts. Credentialing language gets settled in medical board dockets, advisory boards, and public comment periods. Clinics rarely show up to any of them. Operators already running monitoring protocols and consent processes bring regulators a working model instead of a theory.
SAMHSA frames the stakes in one line. “The question is not whether individuals in a particular state will use psychedelics, but whether they will do so in regulated, safe contexts.” Clinics that help answer it will be shaping the rules they later work under. Clinics that sit it out will inherit rules written by people who have never run a session.
READ NEXT: What the FDA’s New Psychedelic Rulebook Means for Ketamine Clinics
